SCM
Silverarc Capital Management Portfolio holdings
AUM
$489M
This Quarter Return
+51.32%
1 Year Return
+71.55%
3 Year Return
+1,109.63%
5 Year Return
–
10 Year Return
–
AUM
$357M
AUM Growth
+$357M
(+10%)
Cap. Flow
-$27M
Cap. Flow
% of AUM
-7.57%
Top 10 Holdings %
Top 10 Hldgs %
41.79%
Holding
95
New
30
Increased
9
Reduced
31
Closed
21
Top Buys
| 1 |
Avidity Biosciences
RNA
|
$12.5M |
| 2 |
C4 Therapeutics
CCCC
|
$11.7M |
| 3 |
Solid Biosciences
SLDB
|
$9.73M |
| 4 |
Perspective Therapeutics
CATX
|
$9.65M |
| 5 |
Crinetics Pharmaceuticals
CRNX
|
$5.98M |
Top Sells
| 1 |
Mersana Therapeutics
MRSN
|
$15.5M |
| 2 |
MacroGenics
MGNX
|
$11.5M |
| 3 |
Medtronic
MDT
|
$11.1M |
| 4 |
Sanofi
SNY
|
$10.9M |
| 5 |
Rocket Pharmaceuticals
RCKT
|
$7.59M |
Sector Composition
| 1 | Healthcare | 99.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Merus
MRUS
$4.98B
| $25.5M | 7.08% | 566,287 -79,294 | -12% | -$3.57M |
|
|
2
Solid Biosciences
SLDB
$427M
| $17.6M | 4.9% | 1,325,065 +730,210 | +123% | +$9.73M |
|
|
MORF
3
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $17M | 4.73% | 483,972 -16,070 | -3% | -$566K |
|
4
Oric Pharmaceuticals
ORIC
$994M
| $15.3M | 4.25% | 1,113,007 -56,993 | -5% | -$784K |
|
|
5
Mersana Therapeutics
MRSN
$36.5M
| $13.3M | 3.69% | 2,968,798 -3,451,338 | -54% | -$15.5M |
|
6
Celldex Therapeutics
CLDX
$1.47B
| $12.6M | 3.49% | 299,316 +52,101 | +21% | +$2.19M |
|
|
7
Avidity Biosciences
RNA
$5.99B
| $12.5M | 3.47% | +489,303 | New | +$12.5M |
|
8
Nuvalent
NUVL
$5.52B
| $11.8M | 3.29% | 157,750 -35,250 | -18% | -$2.65M |
|
|
9
C4 Therapeutics
CCCC
$185M
| $11.7M | 3.26% | +1,435,931 | New | +$11.7M |
|
10
Praxis Precision Medicines
PRAX
$958M
| $11.6M | 3.23% | 190,556 -93,285 | -33% | -$5.69M |
|
|
PSTX
11
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $11.5M | 3.19% | 3,596,476 -109,303 | -3% | -$349K |
|
12
Akero Therapeutics
AKRO
$3.74B
| $10.1M | 2.81% | 399,949 +150,695 | +60% | +$3.81M |
|
|
13
Perspective Therapeutics
CATX
$250M
| $9.65M | 2.68% | +8,108,108 | New | +$9.65M |
|
14
Rhythm Pharmaceuticals
RYTM
$6.85B
| $7.96M | 2.21% | 183,776 +9,528 | +5% | +$413K |
|
|
ALPN
15
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $7.89M | 2.19% | 199,020 -98,769 | -33% | -$3.92M |
|
16
UroGen Pharma
URGN
$900M
| $7.63M | 2.12% | 508,587 -16,817 | -3% | -$252K |
|
17
Gossamer Bio
GOSS
$562M
| $7.23M | 2.01% | 6,130,268 | – | – |
|
|
18
MacroGenics
MGNX
$112M
| $7.04M | 1.95% | 478,079 -780,562 | -62% | -$11.5M |
|
19
Cogent Biosciences
COGT
$1.69B
| $6.97M | 1.93% | 1,036,667 +69,919 | +7% | +$470K |
|
20
KalVista Pharmaceuticals
KALV
$678M
| $6.66M | 1.85% | 561,183 +449,449 | +402% | +$5.33M |
|
21
Kodiak Sciences
KOD
$478M
| $6.52M | 1.81% | 1,238,822 +238,822 | +24% | +$1.26M |
|
22
Veracyte
VCYT
$2.39B
| $6.22M | 1.73% | 280,773 +33,050 | +13% | +$732K |
|
|
23
Crinetics Pharmaceuticals
CRNX
$2.92B
| $5.98M | 1.66% | +127,835 | New | +$5.98M |
|
24
Olema Pharmaceuticals
OLMA
$375M
| $5.83M | 1.62% | 515,317 -58,513 | -10% | -$662K |
|
|
BBOT
25
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
$708M
| $5.2M | 1.44% | +500,000 | New | +$5.2M |
|